Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC Sept 2021 | The need for guidelines on cfDNA analysis in patients with lung cancer

Maria Arcila, MD, Memorial Sloan Kettering Cancer Center, New York, NY, considers some of the major challenges facing the uptake of cell-free DNA (cfDNA) analysis in the clinic for patients with lung cancer. The current lack of international guidelines for the extraction and assessment of cfDNA remains a key challenge that needs to be addressed. Another important consideration is that not all patients shed sufficient levels of DNA into the circulation for detection, meaning negative results must be interpreted with caution to avoid underdiagnosis. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.

Disclosures

Maria Arcila has has participated in a consulting or advisory role for Janssen Global Services, Bristol-Myers Squibb & AstraZeneca. She has also received speaker honoraria from Biocartis, Invivoscribe Inc, Physician Educational Resources, PeerView Institute for Medical Education, Clinical Care Options & RMEI Medical Education.